ArticleOphthalmology and therapy2013
Management of vernal keratoconjunctivitis.
Article in Ophthalmology and therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 120 citations in OpenAlex.
- Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials.Eye (London, England) · 2023Trial
- N-Acetyl-Aspartyl Glutamic Acid (NAAGA)-Based Eye Drops for Contact Lens Wearers with Dry Eye Symptoms and Discomfort.Vision (Basel, Switzerland) · 2025Article
- Injectable PLGA-based In Situ Forming Subconjunctival Implant for Sustained Ocular Delivery of Ketotifen Fumarate: Formulation, Drug Release, and Biocompatibility Studies.AAPS PharmSciTech · 2025Article
- Corticosteroid-sparing topical treatment with cyclosporin for juvenile keratoconjunctivitis.Scientific reports · 2025Article
- Allergen Testing: A Review of the Indications, Procedures, and Limitations in Ocular Allergy.Clinical reviews in allergy & immunology · 2024Review
- Seeing eye to eye: a modified Delphi method-based multidisciplinary expert consensus on the diagnosis and treatment of vernal keratoconjunctivitis.European journal of pediatrics · 2024Article
- Vernal Keratoconjunctivitis: Immunopathological Insights and Therapeutic Applications of Immunomodulators.Life (Basel, Switzerland) · 2024Review
- [An unusual conjunctival lesion].Die Ophthalmologie · 2024Article
- [New and future treatment approaches for allergic conjunctivitis].Die Ophthalmologie · 2024Review
- Vernal keratoconjunctivitis in adults: a narrative review of prevalence, pathogenesis, and management.Frontiers in ophthalmology · 2024Review
- Long-Term Observation of Prognostic Factors and Clinical Outcome of Vernal Keratoconjunctivitis in Childhood.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Article
- Preserved Ophthalmic Anti-Allergy Medication in Cumulatively Increasing Risk Factors of Corneal Ectasia.Biology · 2023Review
- Novel Insights in the Management of Vernal Keratoconjunctivitis (VKC): European Expert Consensus Using a Modified Nominal Group Technique.Ophthalmology and therapy · 2023Article
- Recent progress in N6-methyladenosine modification in ocular surface diseases.International journal of ophthalmology · 2023Review
- Usability of an Eye Drop Delivery Aid for Single-Dose Instillation: Results from a Market Research Study.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- The effect of COVID-19 imposed lockdown on Italian children with Vernal Keratoconjunctivitis.The World Allergy Organization journal · 2022Article
- Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial.Journal of clinical medicine · 2022Article
- Effectiveness of a modified therapeutic protocol for the management of vernal keratoconjunctivitis based on Bonini's graded clinical severity.Indian journal of ophthalmology · 2022Article
- When to start tacrolimus ointment for vernal keratoconjunctivitis? A proposed treatment protocol.International ophthalmology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vernal keratoconjunctivitis (VKC) is a relatively rare, chronic form of ocular allergy that can potentially cause severe visual complications. Affecting mainly children and young adults, it is an IgE- and T cell-mediated disease, leading to a chronic inflammation in which eosinophil, lymphocyte and structural cell activation are involved. Treatment of VKC requires a multiple approach that includes conservative measures and pharmacologic treatment. Patients and parents should be made aware of the long duration of disease, its chronic evolution and possible complications. Treatment should be based on the duration and frequency of symptoms and the severity of corneal involvement. Mast cell stabilizers and antihistamines have been proven to be effective for the treatment of mild to moderate forms of VKC. In the most severe cases, topical steroids can be used as rescue medication to reduce conjunctival and corneal inflammation. Immunomodulators that have been investigated for VKC treatment include topical ocular preparations of cyclosporine A and tacrolimus. Topical cyclosporine A has been proven to be effective in the long-term treatment of VKC, significantly improving signs and symptoms without significant side effects.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.